Literature DB >> 9570556

Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.

K Tsung1, J B Meko, Y L Tsung, G R Peplinski, J A Norton.   

Abstract

Previous studies have demonstrated eradication of small (4-8 mm) established murine MCA207 sarcomas by treatment with systemic IL-12. Analysis of the mechanism has revealed a cellular and molecular immune response at the tumor typical of a Th1 cell-mediated, macrophage-effected, delayed-type hypersensitivity (DTH) response. In the current study we investigate the immune response against long term established, large MCA207 tumors induced by combined treatment with IL-12 and cyclophosphamide (Cy), an agent known to potentiate the DTH response. Our results demonstrate that s.c. large MCA207 tumors (15-20 mm) that are refractory to treatment by either IL-12 or Cy alone can be completely eradicated by the combination of Cy and IL-12. IL-12 is apparently the only cytokine capable of mediating tumor eradication, and the effect is dependent on IFN-gamma. The contribution of Cy is probably due to immunopotentiation of DTH rather than to direct cytotoxicity to the tumor. The regression of these large tumors takes >4 wk and, in many cases, is self-sustained, in that little or no additional IL-12 is needed beyond the initial week of administration. Analysis of the cellular and molecular events at the tumor site suggests that the mechanism is a Th1-mediated antitumor immune response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570556

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy.

Authors:  Mike W Helms; Jennifer A Prescher; Yu-An Cao; Steven Schaffert; Christopher H Contag
Journal:  Cancer Immunol Immunother       Date:  2010-06-09       Impact factor: 6.968

2.  Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma.

Authors:  Wesley Hsu; Maciej S Lesniak; Betty Tyler; Henry Brem
Journal:  J Neurooncol       Date:  2005-09       Impact factor: 4.130

Review 3.  Interleukin-12 as an in situ cancer vaccine component: a review.

Authors:  Emily M Cheng; Noah W Tsarovsky; Paul M Sondel; Alexander L Rakhmilevich
Journal:  Cancer Immunol Immunother       Date:  2022-01-13       Impact factor: 6.630

Review 4.  The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

Authors:  William Humphries; Jun Wei; John H Sampson; Amy B Heimberger
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

5.  In situ vaccine, immunological memory and cancer cure.

Authors:  Kangla Tsung; Jeffrey A Norton
Journal:  Hum Vaccin Immunother       Date:  2015-09-11       Impact factor: 3.452

Review 6.  Ribavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte function.

Authors:  Richard E Kast
Journal:  Neoplasia       Date:  2003 Jan-Feb       Impact factor: 5.715

7.  A multipurpose brachytherapy catheter to enable intratumoral injection.

Authors:  Justin C Jagodinsky; Gabriella Medeiros; Hayley H Raj; Amira Razuan; Alexis Locsin; Tirhas G Dempsey; Beixiao Tang; Ishan Chakravarty; Paul A Clark; Raghava N Sriramaneni; Won Jong Jin; Keng-Hsueh Lan; Rupak K Das; Jessica R Miller; Darilis Suarez-Gonzalez; Zachary S Morris
Journal:  Brachytherapy       Date:  2021-03-27       Impact factor: 2.441

8.  Tumor rejection by disturbing tumor stroma cell interactions.

Authors:  S Ibe; Z Qin; T Schüler; S Preiss; T Blankenstein
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

Review 9.  The mechanism of the anticancer function of M1 macrophages and their use in the clinic.

Authors:  Xing-Qing Pan
Journal:  Chin J Cancer       Date:  2012-11-13

10.  Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.

Authors:  Ting Yue; Xiaodong Zheng; Yaling Dou; Xiaohu Zheng; Rui Sun; Zhigang Tian; Haiming Wei
Journal:  BMC Cancer       Date:  2016-08-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.